DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival

Yuliang Su\textsuperscript{a}  Huan Zhang\textsuperscript{a}  Fangxiu Xu\textsuperscript{a}  Jinyu Kong\textsuperscript{a}  Herbert Yu\textsuperscript{b}  Biyun Qian\textsuperscript{a,c}

\textsuperscript{a}Department of Cancer Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer; Key Laboratory of Cancer Prevention and Therapy, Ministry of Education, Tianjin, China; \textsuperscript{b}Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA; \textsuperscript{c}School of Public Health, Shanghai Jiao Tong University, Shanghai, China

Key Words
Lung cancer • hOGG1 • XPA • Polymorphism • Survival

Abstract
Background: Single nucleotide polymorphisms (SNPs) in the DNA repair genes are suspected to be related to the survival of lung cancer patients due to their possible influence on DNA repair capacity (DRC). However, the study results are inconsistent. Methods: A follow-up study of 610 non-small cell lung cancer (NSCLC) patients was conducted to investigate genetic polymorphisms associated with the DNA repair genes in relation to NSCLC survival; 6 SNPs were genotyped, including \textit{XRCC1} (rs25487 G>A), \textit{hOGG1} (rs1052133 C>G), \textit{MUTYH} (rs3219489 G>C), \textit{XPA} (rs1800975 G>A), \textit{ERCC2} (rs1799793 G>A) and \textit{XRCC3} (rs861539 C>T). Kaplan-Meier survival curve and Cox proportional hazards regression analyses were performed. SNP-SNP interaction was also examined using the survival tree analysis. Results: Advanced disease stage and older age at diagnosis were associated with poor prognosis of NSCLC. Patients with the variant 'G' allele of \textit{hOGG1} rs1052133 had poor overall survival compared with those with the homozygous wild 'CC' genotype, especially in female patients, adenocarcinoma histology, early stage, light smokers and without family history of cancer. For never smoking female lung cancer patients, individuals carrying homozygous variant 'AA' genotype of \textit{XPA} had shorter survival time compared to those with wild 'G' alleles. Furthermore, females carrying homozygous variant \textit{XPA} and \textit{hOGG1} genotypes simultaneously had 2.78-fold increased risk for death. Among all 6 polymorphisms, the homozygous variant 'AA' of \textit{XPA} carriers had poor prognosis compared to the carriers of wild 'G' alleles of \textit{XPA} together with other base excision repair (BER) polymorphisms. Conclusions: Besides disease stage and age, the study found DNA repair gene polymorphisms were associated with lung cancer survival.

Copyright © 2015 S. Karger AG, Basel
Su et al.: DNA Repair Gene SNPs and NSCLC Survival
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2015;36:1419-1429
DOI: 10.1159/000430307
Published online: July 06, 2015
© 2015 S. Karger AG, Basel
www.karger.com/cpb

Introduction

Lung cancer is one of the most commonly diagnosed malignancies, and remains to be the leading cause of cancer-related mortality globally. Each year there are 1,095,000 new male cases and 951,000 deaths in men, and 513,600 new female cases and 427,400 deaths in women [1]. Survival from lung cancer has slowly been improved during the past decade, but the prognosis remains poor (5-year survival only 10%) [2]. Tobacco smoking is the most significant cause of lung cancer, and DNA damage induced by tobacco carcinogens is considered an important pathogenic pathway involved in lung carcinogenesis. Recent research indicates that single nucleotide polymorphisms (SNPs) in the DNA repair genes may influence DNA repair capacity (DRC), and therefore affect the risk of lung cancer and survival of patients [3, 4]. Although previous studies focused largely on Asians and less on Caucasians, evidence supporting the genetic involvement of DNA repair genes in lung cancer risk and survival remains inconclusive; more studies with large sample size are still needed. We previously completed a case-control study analyzing the DNA repair gene polymorphisms in relation to lung cancer risk in a Chinese population, and found evidence of associations between some of the SNPs and lung cancer [5]. Based on the hypothesis that DNA repair capacity may also influence lung cancer patient survival, we selected 6 common SNPs which are located either in the coding regions or promoter of the genes, including XRCC1 Arg399Gln (rs25487 G>A) in 19p13.2, hOGG1 Ser326Cys (rs1052133 C>G) in 3q26.2, MUTYH Gln324His (rs3219489 G>C) in 1p34.1, XPA (rs1800975 G>A) in 9q22.3, ERCC2 Asp312Asn (rs1799793 G>A) in 19q13.3 and XRCC3 Thr241Met (rs861539 C>T) in 14q32.3. These genes belong to three DNA repair pathways, and the chosen SNPs have been suggested to have impacts on DRC, which may have influence on lung cancer patient survival.

Specifically, XRCC1, which is involved in the repair of single strand breaks following the base excision repair (BER) pathway, is a scaffold like protein which helps to remove the DNA adducts. XRCC1 (rs25487 G>A), the most characterized and extensively studied SNP, has been evaluated in a number of studies with regard to NSCLC survival. Previous studies reported that this SNP has an association with DNA repair activity [6, 7]. HOGG1 regulates the excision and removal of 8-OH-dG adducts through the BER pathway. The hOGG1(rs1052133 C>G) SNP may influence the DNA repair capacity as the mutant genotype has a reduced protein activity [8]. MUTYH acts as a counterpart of hOGG1 in repairing the oxidative DNA damage. Although previous study has reported that a SNP in the gene, MUTYH (rs3219489 G>C), has no association with survival in Japanese lung cancer patients [9], we considered this evaluation should be repeated. XPA encodes a zinc-finger DNA-binding protein which involves both global genome and transcription-coupled repair pathways and plays central roles in the nucleotide excision repair (NER) pathway. A polymorphism rs1800975 located in the fourth nucleotide upstream from the initiation codon (ATG) was found to affect DNA repair capacity in a host cell reactivation assay [10]. ERCC2 encodes a helicase which is subunit of the NER machinery, and has been well studied in lung cancer. The SNP (rs1799793 G>A) in ERCC2 was shown to affect DRC [11]. The protein encoded by XRCC3 belongs to the double-strand break repair (DSBR) pathway which repairs the DNA damages caused by ionizing irradiation and oxidative free radicals. A polymorphism in codon 241 (rs861539 C>T) of XRCC3 has been linked to an increased level of DNA adducts in healthy people [7]. Based on the evidence, we selected these SNPs to examine their associations with lung cancer survival in a Chinese population.

Materials and Methods

Study subjects

A patient cohort of lung cancer was established between January 2006 and July 2010, and the project was approved by the ethical review committee at the Tianjin Medical University Cancer Hospital. During the study, blood samples were collected consecutively from the patients who underwent surgery for lung cancer.
at the Tianjin Medical University Cancer Hospital. Clinical and pathological information was obtained from medical records and pathology reports of the patients, including age of diagnosis, histological type, tumor size, disease stage, lymph node metastasis, chemotherapies and other demographic information. All patients had previously been diagnosed, and histologically confirmed primary non-small cell lung cancer. Furthermore, patients with a previous medical history of cancer, radiotherapy or chemotherapy were excluded. Face-to-face or telephone interviews to patients or their family members were conducted to ascertain information on tobacco use and survival status. Surrogate persons who obtained patients’ information from must live with the patients or take care of the patients after cancer was diagnosed. Information on tobacco use includes smoking status, age at first use, years of smoking, number of cigarettes smoked per day, and the status and age of quitting smoking. Individuals who smoked at least one cigarette per day for half a year were considered smokers. Individuals who smoked less than 100 cigarettes in their whole life were considered never smoker.

Genotyping
Peripheral blood leukocytes obtained from the buffy coat of 1mL of whole blood sample was used for DNA extraction. Genomic DNA was isolated using the DNA Blood Mini kit (Qiagen, Valencia, CA) according to the manufacturer’s instruction. The SNPs of XRCC1 (rs25487 G>A), hOGG (rs1052133 C>G), and MUTYH (rs3219489 G>C) from the BER pathway; XPA (rs1800975 G>A) and ERCC2 (rs1799793 G>A) from the NER pathway and XRCC3 (rs861539 C>T) from the DSB pathway were genotyped with a polymerase chain reaction (PCR)-based on fluorescence 5'nuclease assay (TaqMan) described previously [5].

In the genotype analysis, about 5% of the samples were randomly selected for repeat, and the results were in agreement with the original results. The genotyping results were also validated by direct sequencing of the PCR products.

Statistical analysis
The associations between overall survival and individual SNPs were evaluated using the Kaplan-Meier method and the Log-rank test. Hazard ratios (HR) and their 95% confidence interval (CI) were calculated from the Cox proportional hazards regression model. Both univariate and multivariate analyses were performed. The multivariate model included age at diagnosis, gender, histology type, disease stage, treatment and type of surgery. Since patients with different stage of disease may receive different treatment after surgery, we also included treatment and the type of surgery in the multivariate survival analysis for adjustment. All statistical analyses were two-sides and \( P \) values<0.05 were considered statistically significant. Statistical software SAS 9.1 (SAS, Cary, NC) was used for data analysis. In order to evaluate the high order gene-gene interactions and to obtain subgroups with distinct death risk, survival tree analysis was performed. In the survival tree analysis, we examined all the covariates and chose the split nodes that had the best separation of homogeneous groups. Tree building and tree pruning were carried out with the R (version 2.13.0) software for statistical computing using the part packages.

Results

Patient characteristics and clinical features
The median follow-up time of the patients was 28 months ranging from 1 to 56 months. Of the 610 patients, there were 222 deaths and 25 lost to follow-up. Table 1 summarized the clinical features of the patients. The mean age of patients at diagnosis was 60.30±9.14 years, ranging from 23 to 83 years. The 2-year overall survival rate was 71.67%. As anticipated, younger patients had longer survival time compared with the older ones. The results of Cox regression analyses indicated that the risk of death was nearly 3-fold higher in the patients with stage III-IV diseases compared with those with stage I-II (HR=2.91, 95%CI:2.20-3.86) after adjusting for age, gender, histological type, treatment and type of surgery. Furthermore, we divided the treatment into surgery, surgery + chemotherapy, surgery+ radiotherapy, surgery +chemotherapy +radiotherapy and found that patients who took surgery+ chemotherapies and surgery+ radiotherapy had lower risk of death than those who took only surgery as treatment (HR=0.62 and 0.57, respectively). No significant differences in survival
were observed among patients with different gender, histology, family history of cancer, smoking status or chemotherapy types after adjustment.

**DNA repair gene polymorphisms**

The genotype frequencies of the investigated SNPs listed in Table 2 were all in Hardy-Weinberg equilibrium. Of the 6 SNPs genotyped in our study, we only found that the variant ‘CG+GG’ genotype of *hOGG1* (rs1052133 C>G) was associated with survival of lung cancer when comparing to the wild ‘CC’ genotype (Log-rank P value=0.026). However, this significance disappeared after adjusting for age at diagnosis, gender, disease stage, histological type and treatment. We further stratified the association of the *hOGG1* (rs1052133 C>G) SNP and lung cancer survival by several covariates. Table 3 shows that the following patients who carried *hOGG1* variant ‘G’ allele had poor prognosis for lung cancer, early stage (HR=2.22, 95%CI: 1.11-4.44), age (<60 years) (HR=2.02, 95%CI: 1.04-3.92), adenocarcinoma (HR=2.55, 95%CI: 1.11-5.86) and without family history of cancer (HR=1.60,95%CI: 1.04-2.45).

Among the smokers, patients who carried *hOGG1* variant ‘G’ allele had a shorter survival time compared to those with wild homozygote, but the difference was not significant (Log-rank P value= 0.072, data not shown). Furthermore, when further dividing the smokers into light and heavy ones according to the smoking amount (pack-year), we found that light smokers with less than 40 pack-year who carried variant ‘G’ allele had nearly 2.6 times higher risk of death compared to those carrying the wild ‘CC’ genotype (HR=2.63, 95%CI: 1.05-6.59). However, we found no significant association among the heavy smokers.

**Table 1.** Patient characteristics and clinical features. a: adjusted by gender, treatment and type of surgery. b: adjusted by age, treatment and type of surgery. c: SCC (Squamous cell carcinomas); ACC (Adenocarcinomas). d: TP(Taxol+Platinum); NP (Vinorelbine+Platinum); GP (Gemcitabine+Platinum); DP (docetaxel+platinum). e: adjusted by age, gender, histological type, stage, treatment and type of surgery. f: adjusted by age, gender, histological type, stage and type of surgery. treatment refer to surgery, surgery+chemotherapy, surgery+radiotherapy, surgery+chemotherapy+radiotherapy. g: data is partly missing
Since female lung cancer is believed to be a distinct disease from male lung cancer based on epidemiological and biological evidence, we further evaluated the association of DNA repair gene polymorphisms and lung cancer survival only among female patients (Table 2).

Our results indicated that female patients carrying variant 'AA' genotype of the XPA gene had a 2-fold increase in risk for death compared to those with the wild 'G' allele (HR=1.72, 95%CI:1.02-2.90). The association for hOGG1 was borderline significant. Kaplan-Meier

### Table 2. Polymorphisms in DNA repair pathway genes and survival of patients.

| Genotypes | Number (%) | Log-rank p value | HR (95%CI) | Adjusted HR (95%CI) |
|-----------|------------|-----------------|------------|---------------------|
|           | All (n=110) | Female (n=59)   | All Female | All Female          |
| BRAF      | GG          | 341 (55.9%)     | 111 (55.9%) | 1.00                | 1.00                |
|           | GA          | 232 (38.3%)     | 73 (36.8%)  | 1.24 (0.94-1.62)  | 1.24 (0.94-1.62)  |
|           | AA          | 37 (6.0%)       | 13 (6.9%)   | 0.80 (0.40-1.53)  | 0.80 (0.40-1.53)  |
| hOGG1     | GG          | 660 (44.1%)     | 157 (57.4%) | 1.00                | 1.00                |
|           | GA          | 269 (17.6%)     | 82 (27.0%)  | 1.22 (0.90-1.63)  | 0.99 (0.74-1.34)  |
|           | AA          | 206 (14.0%)     | 55 (18.9%)  | 1.00                | 1.00                |
|           | CCG         | 981 (67.6%)     | 31 (75.5%)  | 1.00                | 1.00                |
|           | CG          | 365 (58.9%)     | 108 (54.7%) | 1.00                | 1.00                |
|           | GC          | 207 (33.3%)     | 69 (38.5%)  | 1.00                | 1.00                |

Since female lung cancer is believed to be a distinct disease from male lung cancer based on epidemiological and biological evidence, we further evaluated the association of DNA repair gene polymorphisms and lung cancer survival only among female patients (Table 2).

Our results indicated that female patients carrying variant 'AA' genotype of the XPA gene had a 2-fold increase in risk for death compared to those with the wild 'G' allele (HR=1.72, 95%CI:1.02-2.90). The association for hOGG1 was borderline significant. Kaplan-Meier
Fig. 1. Kaplan-Meier curves for female nonsmokers by XPA rs1800975 genotypes. The patients who carried the XPA rs1800975 homozygous variant ‘AA’ genotype have poor survival than those who carried ‘GG’ or ‘GA’ genotype (Log-rank P=0.021).

Table 4. Association between hOGG1 and XPA polymorphism on female lung cancer patients survival. a: adjusted by age, histological type, stage, treatment and type of surgery

| Gene-variants | XPA-GG+GA | XPA-AA |
|---------------|-----------|--------|
| **XRCC1(rs25487)** |           |        |
| GG+GA         | 145(72.86%) | 1.00   |
| AA            | 11(5.53%)   | 1.24(0.44-3.48) |
| **hOGG1(rs1052133)** |           |        |
| CC+CG         | 110(55.28%) | 1.00   |
| GG            | 46(23.12%)  | 1.82(1.00-3.28) |
| **MUTYH(rs3219489)** |           |        |
| GG+GC         | 131(65.83%) | 1.00   |
| CC            | 25(12.56%)  | 0.91(0.40-2.05) |

Survival tree analysis showed that patients with different XPA genotypes had quite different survival curves (Log-rank test, P=0.021, Fig. 1). In contrast, no significant differences in survival were observed among male patients (data not shown).

**Gene-gene interactions**

We further analyzed the SNP-SNP interaction in association with lung cancer survival. When we conducted stratified analysis by the XPA genotype, we found that the variant XPA carriers had higher risk for lung cancer death if these subjects also had the homozygous variant ‘GG’ genotype of hOGG1 compared to those who had wild alleles(HR=2.78; 95%CI: 1.19-6.54) (Table 4). We didn't find any significant associations when including either XRCC1 or MUTYH polymorphisms in the analysis.

Survival tree analysis was introduced by Segal in 1988, and then was widely used in identifying subgroups of individuals at higher risk to certain diseases especially cancer [12, 13]. The analysis is based on recursive partitioning, and its graphical output makes it possible to visualize the prognostic subgroups of gene-gene interactions. The analysis is also known as an extension of recursive partitioning for censored survival data. The process is to split the covariate space into regions by a full likelihood estimation and to split the dataset
Su et al.: DNA Repair Gene SNPs and NSCLC Survival

Cellular Physiology and Biochemistry

Fig. 2. Survival tree analysis of all investigated genes in female never smoking lung cancer patients. Figure 2 displays the resultant tree among female never smoking patients after a variety of multivariate survival tree analysis of all the DNA repair pathway genes were computed. Node 1 was chose as reference, Node 3 has 2.18 fold risk of death when compared with node 1, while Node 4 had 2.37 fold death risk.

Discussion

Consistent with the literature, we found advanced disease stage and older ages at diagnosis were independently associated with NSCLC survival in our study. We also detected a possible association between DNA repair gene polymorphisms and overall survival of lung cancer among Chinese patients. The variant 'G' allele of $hOGG1$ rs1052133 was associated with increased risk of death, especially in female, early stage disease, adenocarcinoma, light smokers, or patients without a family history of cancer. Moreover, for female patients, the genetic polymorphism of $XPA$ rs1800975 was shown some influences on lung cancer survival besides the BER gene polymorphism.

A significant association between the $hOGG1$ (rs1052133 C>G) polymorphism and increased lung cancer susceptibility was demonstrated in a meta-analysis [14]. Genetic polymorphisms have emerged as a risk factor not only for cancer development, but also for cancer progression and prognosis [15]. A study reported by Shen et al. showed that patients with the variant 'CG/GG' genotypes of $hOGG1$ had a shorter survival time compared to those with the wild 'CC' genotype, although the difference was not significant (Log-rank $p=0.098$) [16]. In vitro experiments demonstrated that the variant 'G' allele of $hOGG1$ was associated with higher level of 8-OH-dG protein, but lower enzymatic activity of 8-OH-dG compared to the wildtype 'C' allele [17, 18]. In addition, the $hOGG1$ protein encoded by the 'G' allele could promote the accumulation of oxidative adducts, such as 8-oxo-G, which might increase the mutation rates [19]. Based on these findings, it is not surprised that lung cancer patients
who carried the hOGG1 ‘G’ allele might have poor survival outcomes. Our study did show that patients carrying the hOGG1 variant ‘G’ allele had poor survival, which was especially evident in female patients, early stage of cancer, adenocarcinoma, light smokers, and those without a family history of cancer. Our results were basically consistent with those observed by Shen et al., except for a few small differences which were probably due to different sample sizes, ethnic variations, and less prevalence of the ‘G’ allele in the Caucasian population.

It is well known that smoking is the predominant risk factor of lung cancer. However, not all lung cancer patients have a history of smoking, especially for female patients. Females are more likely than males to have non-smoking lung cancer, although the etiology of lung cancer for non-smoking females is unclear. Based on different epidemiological and biological features between male and female lung cancer patients, female lung cancer has been suggested to be treated differently as a distinct disease [1, 20-22]. That notion is further confirmed by molecular and genetic analysis which show unique features of methylation index and mutations in P53, EGFR and KRAS [23]. Our results suggested that XPA (rs1800975 G>A) polymorphism had a possible influence on lung cancer survival among female patients in addition to the polymorphism of hOGG1 gene. Moreover, survival tree analysis which showed good discriminative survival profiles from different gene variation further indicated the combined effect of XPA and hOGG1 on survival outcomes.

Our previous study showed that the variant ‘AA’ genotype of XPA was significantly associated with increased risk of NSCLC [5], and this association was also supported by a large meta-analysis [24]. Similar to our results, some studies suggested the variant ‘A’ allele of XPA rs1800975 was a risk factor for survival in lung cancer [25-28]. One study focused on younger patients and ever smokers with less than 36 pack-year [25]. Other studies indicated that the ‘A’ allele-associated unfavorable overall survival of NSCLC may be related to the poor response of patients to treatment [26-28]. XPA polymorphisms had been reported to affect patient response to platinum-based chemotherapy [29].

The SNP at XPA (rs1800975 G>A), is particularly interesting because it is located in the region near the transcription initiation codon at the 5’UTR, and it may affect the transcription of the XPA gene which plays a critical role in the NER pathway. In addition, this substitution may remove a CpG site, which can interfere with methylation of the XPA promoter and proper regulation of XPA expression [30]. The XPA allele may also be in linkage disequilibrium with some alleles from the adjacent genes which are susceptible for survival outcomes [26, 31]. Finally, a recent study found that the XPA (rs1800975 G>A) SNP may alter the occurrence of TP53 mutations in lung cancer, which can lead to a more aggressive phenotype, resulting in poor survival [32]. However, functional evaluations and population studies are still needed to explain the finding of our study in female non-smoking patients.

It has been reported that XRCC1 rs25487 is associated with the survival of non-smoking female patients with lung adenocarcinoma [33]. However, we did not find a similar association in our results. Different findings between studies may be due to patient differences with regard to their treatment -46% of patients received chemotherapy in our study, while 88% of patients received chemotherapy or radiotherapy in the other study. Treatment may influence the course of tumor progression. For the polymorphisms of MUTYH, ERCC2, and XRCC3, we found no significant associations with lung cancer survival. These results were similar to those of previous studies [34, 35].

Poor survival in NSCLC is partly attributed to drug resistance. It has been reported that genetic Variants and protein expressions might affect the platinum-based chemotherapy response and prognosis of advanced NSCLC patients [36, 37]. Platinum-based chemotherapy as a main treatment for lung cancer exerts its anti-cancer effect largely through the formation of bulky platinum-DNA adducts, which result in destabilization of the DNA double helix that otherwise blocks replication and inhibits transcription. Since adduct-induced DNA damage is repaired mainly by NER and BER, these DNA repair functions play an important role in determining the sensitivity of tumor cells to platinum treatment [38]. Polymorphisms in the DNA repair pathway genes, such as ERCC1, XRCC1, ERCC2 and XRCC3, may affect the activities of DNA repair and therefore influence patient’s response to platinum-based chemotherapy.
ultimately impacting on disease outcomes and patient survival [27, 38-44]. The complexity of the DNA repair mechanisms along with the heterogeneity of tumor cells, however, may complicate our effort to understand the effect of genetic polymorphisms on DNA repair functions and substantially on patient’s response to chemotherapy which is based the DNA damage mechanisms. Despite the complication, we did find evidence to support the possibility that genetic polymorphisms involved in DNA repair capacity may affect treatment influencing patient survival.

Our study, however, was still relatively small and had limited follow-up time. The observations were retrospective without sufficient control for confounding. To confirm our findings, prospective studies with larger sample size and longer follow-up time are needed with adjustment for more confounding variables. The detailed mechanisms of chemotherapy-induced DNA damage and repair remain to be elucidated.

In conclusion, for non-smoking female NSCLC, genetic polymorphisms in the NER pathway may play a role in survival. SNPs both in NER and BER may have a joint effect on NSCLC survival.

**Abbreviations**

SNPs (Single Nucleotide Polymorphisms); DRC (DNA Repair Capacity); NSCLC (Non-Small Cell Lung Cancer); BER (Base Excision Repair); PCR (Polymerase Chain Reaction); HR (Hazard Ratios); CI (Confidence Interval).

**Acknowledgements**

This work was supported by National Natural Science Foundation of China (No. 81372229) and Natural Science Foundation of Shanghai (No. 15ZR1424400).

**Disclosure Statement**

All authors have read and approved the paper for submission. We declare no conflict of interest.

**References**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R: EUROCare-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931-991.
3. Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H: Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 2003;9:2294-2299.
4. Sun Z, Chen J, Aakre J, Marks RS, Garces YY, Jiang R, Idowu O, Cunningham JM, Liu Y, Pankratz VS, Yang P: Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010;21:2011-2016.
5. Qian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K: Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2011;73:138-146.
Abdel-Rahman SZ, El-Zein RA: The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000;159:63-71.

Matullo G, Palli D, Peluso M, Guerrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vinesis P: XRCC1, XRCC3, XPD gene polymorphisms, smoking and [32]P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437-1445.

Hill JW, Evans MK: Dimerization and opposite base-dependent catalytic impairment of polymorphic S326C OGG1 glycosylase. Nucleic Acids Res 2006;34:1620-1632.

Oswa K, Nakarai C, Uchino K, Yoshimura M, Tsubota N, Takahashi J, Kido Y: XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients. Int J Mol Sci 2012;13:16658-16667.

Wu X, Zhao H, Wei Q, Amos CI, Zhang K, Guo Z, Qiao Y, Hong WK, Spitz MR: XPA polymorphism associated with reduced effect on nucleotide excision repair capacity. Carcinogenesis 2003;24:505-509.

Affatato AA, Wolfe KJ, Lopez MS, Hallberg C, Ammenheuser MM, Abdel-Rahman SZ: Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco-specific nitrosamine NNK. Environ Mol Mutagen 2004;44:65-73.

Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, Gu J, Hong WK, Stewart D, Spitz MR: Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008;18:955-965.

Dai J, Gu J, Lu C, Lin J, Stewart D, Chang D, Roth JA, Wu X: Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. PLoS One 2011;6:e21120.

Zhong D, Li G, Long J, Wu J, Hu Y: The hOGG1Ser326Cys polymorphism and increased lung cancer susceptibility in Caucasians: an updated meta-analysis. Sci Rep 2012;2:548.

Loktionov A: Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004;208:1-33.

Shen J, Deininger P, Hunt JD, Zhao H: 8-Hydroxy-2’-deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with nonsmall-cell lung cancer. Cancer 2007;109:574-580.

Kohno T, Shimura K, Tosaka M, Tani M, Kim SR, Sugimura H, Nohmi T, Kasai H, Yokota J: Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998;16:3219-3225.

Bravard A, Vacher M, Moritz E, Vaslin L, Hall J, Epe B, Radicella JP: Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res 2009;69:3642-3649.

Rihs HP, Marczynski B, Lotz A, Raulf-Heimsoth M, Bruning T: Modulation of oxidative DNA damage by repair enzymes XRCC1 and hOGG1. J Toxicol Environ Health A 2012;75:588-596.

Yang GH, Wang JF, Wan X, Wang LJ, Chen AP: [Quantitative analysis of factors affected mortality trend in Chinese, 2002]. Zhonghua Liu Xing Bing Xue Za Zhi 2005;26:934-938.

Heigener DF: Non-small cell lung cancer in never-smokers: a new disease entity? Onkologie 2011;34:202-207.

Subramanian J, Govindan R: Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008;9:676-682.

Kiyohara C, Yoshimasu K: Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007;4:59-71.

Butkiewicz D, Rusin M, Sikora B, Lach A, Chorazy M: An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep 2011;38:5231-5241.

Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J, Zhou Y: XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 2009;41:429-435.
27 Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, Lu Z, Chen B: Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method. Technol Cancer Res Treat 2013;12:473-482.
28 Butkiewicz D, Droisik A, Suwinski R, Krzesniak M, Rusin M, Kosarewicz A, Rachtań J, Matuszczyk I, Gawlowska-Suwinska M: Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer 2012;131:E1100-1108.
29 Osawa K: Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 2009;12:837-840.
30 Candiloro IL, Dobrovic A: Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Philadelphia) 2009;2:862-867.
31 Butkiewicz D, Krzesniak M, Vaitiekunaite R, Sikora B, Bowman ED, Harris CC, Rusin M: A functional analysis of G23A polymorphism and the alternative splicing in the expression of the XPA gene. Cell Mol Biol Lett 2010;15:611-629.
32 Cho S, Kim MJ, Choi YY, Yoo SS, Lee WK, Lee EJ, Jang EJ, Bae EY, Jin G, Jeon HS, Lee SY, Cha SL, Park TI, Kim CH, Park YJ: Associations between polymorphisms in DNA repair genes and TP53 mutations in non-small cell lung cancer. Lung Cancer 2011;73:25-31.
33 Yin Z, Zhou B, He Q, Li M, Guan P, Li X, Cui Z, Xue X, Su M, Ma R, Bai W, Xia S, Jiang Y, Xu S, Lu Y: Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer 2009;9:439.
34 Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulis V, Mavroudis D: DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009;10:118-123.
35 de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, Massuti B, Queralt C, Botia M, Garcia-Gomez R, Isla D, Cobo M, Santarpia M, Cecere F, Mendez P, Sanchez JJ, Rosell R: Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-675.
36 Shi C, Qian J, Ma M, Zhang Y, Han B: Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patients. Cell Physiol Biochem 2014;34:743-752.
37 Wu F, Zhang J, Liu Y, Zheng Y, Hu N: HIF1alpha genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol Biochem 2013;32:1566-1576.
38 Sullivan I, Salazar J, Majem M, Pallares C, Del Rio E, Paez D, Baiget M, Barnadas A: Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014;353:166-166.
39 Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia E, Zanelli F, Fontanini G, Naldini N, Campanini N, Azzoni A, Cioni C, Ardizzoni A: ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 2013;108:1695-1703.
40 Ke HG, Li J, Shen Y, You QS, Yan Y, DongHX, Liu JH, Shen ZY: Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev 2012;13:4413-4416.
41 Ke HG, Li J, Shen Y, You QS, Yan Y, DongHX, Liu JH, Shen ZY: Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev 2012;13:4413-4416.
42 Ke HG, Li J, Shen Y, You QS, Yan Y, DongHX, Liu JH, Shen ZY: Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients. Asian Pac J Cancer Prev 2012;13:4413-4416.
43 Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ: Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol 2012;7:973-981.
44 Xu TP, Shen H, Liu LX, Shu YQ: Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 2013;526:265-274.
45 Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D: Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. PLoS One 2012;7:e33200.
46 Li XD, Han JC, Zhang YJ, Li HB, Wu XY: Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev 2013;14:145-148.